vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.

NexPoint Real Estate Finance, Inc. is the larger business by last-quarter revenue ($11.1M vs $11.0M, roughly 1.0× C4 Therapeutics, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -186.0%, a 402.6% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs -48.8%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.

CCCC vs NREF — Head-to-Head

Bigger by revenue
NREF
NREF
1.0× larger
NREF
$11.1M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+161.6% gap
CCCC
112.8%
-48.8%
NREF
Higher net margin
NREF
NREF
402.6% more per $
NREF
216.6%
-186.0%
CCCC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCCC
CCCC
NREF
NREF
Revenue
$11.0M
$11.1M
Net Profit
$-20.5M
$24.0M
Gross Margin
Operating Margin
-210.1%
Net Margin
-186.0%
216.6%
Revenue YoY
112.8%
-48.8%
Net Profit YoY
40.7%
58.7%
EPS (diluted)
$-0.09
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
NREF
NREF
Q4 25
$11.0M
$11.1M
Q3 25
$11.2M
$12.5M
Q2 25
$6.5M
$12.1M
Q1 25
$7.2M
$11.5M
Q4 24
$5.2M
$21.7M
Q3 24
$15.4M
$12.5M
Q2 24
$12.0M
$6.7M
Q1 24
$3.0M
$-12.8M
Net Profit
CCCC
CCCC
NREF
NREF
Q4 25
$-20.5M
$24.0M
Q3 25
$-32.2M
$50.9M
Q2 25
$-26.0M
$22.3M
Q1 25
$-26.3M
$26.0M
Q4 24
$-34.6M
$15.2M
Q3 24
$-24.7M
$23.3M
Q2 24
$-17.7M
$12.1M
Q1 24
$-28.4M
$-14.6M
Operating Margin
CCCC
CCCC
NREF
NREF
Q4 25
-210.1%
Q3 25
-306.4%
Q2 25
-441.0%
Q1 25
-402.9%
Q4 24
-728.4%
Q3 24
-183.9%
Q2 24
-178.6%
Q1 24
-1060.2%
Net Margin
CCCC
CCCC
NREF
NREF
Q4 25
-186.0%
216.6%
Q3 25
-286.4%
407.0%
Q2 25
-402.6%
184.5%
Q1 25
-363.7%
225.6%
Q4 24
-667.8%
69.9%
Q3 24
-160.6%
186.4%
Q2 24
-147.6%
179.7%
Q1 24
-933.2%
114.3%
EPS (diluted)
CCCC
CCCC
NREF
NREF
Q4 25
$-0.09
$0.47
Q3 25
$-0.44
$1.14
Q2 25
$-0.37
$0.54
Q1 25
$-0.37
$0.70
Q4 24
$-0.50
$0.71
Q3 24
$-0.35
$0.74
Q2 24
$-0.26
$0.40
Q1 24
$-0.41
$-0.83

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
NREF
NREF
Cash + ST InvestmentsLiquidity on hand
$74.6M
$31.1M
Total DebtLower is stronger
$771.2M
Stockholders' EquityBook value
$256.6M
$388.0M
Total Assets
$359.1M
$5.3B
Debt / EquityLower = less leverage
1.99×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
NREF
NREF
Q4 25
$74.6M
$31.1M
Q3 25
$58.8M
$17.9M
Q2 25
$78.2M
$9.1M
Q1 25
$51.3M
$19.2M
Q4 24
$55.5M
$3.9M
Q3 24
$59.6M
$34.7M
Q2 24
$73.1M
$4.3M
Q1 24
$89.7M
$13.5M
Total Debt
CCCC
CCCC
NREF
NREF
Q4 25
$771.2M
Q3 25
$720.9M
Q2 25
$815.6M
Q1 25
$831.5M
Q4 24
$799.3M
Q3 24
$815.5M
Q2 24
$861.0M
Q1 24
$843.3M
Stockholders' Equity
CCCC
CCCC
NREF
NREF
Q4 25
$256.6M
$388.0M
Q3 25
$154.4M
$375.4M
Q2 25
$174.1M
$348.2M
Q1 25
$195.1M
$343.7M
Q4 24
$216.0M
$336.5M
Q3 24
$242.7M
$335.8M
Q2 24
$247.1M
$327.5M
Q1 24
$258.3M
$327.1M
Total Assets
CCCC
CCCC
NREF
NREF
Q4 25
$359.1M
$5.3B
Q3 25
$265.5M
$5.3B
Q2 25
$296.5M
$5.4B
Q1 25
$319.5M
$5.4B
Q4 24
$349.6M
$5.4B
Q3 24
$376.1M
$5.7B
Q2 24
$381.1M
$6.6B
Q1 24
$398.4M
$7.1B
Debt / Equity
CCCC
CCCC
NREF
NREF
Q4 25
1.99×
Q3 25
1.92×
Q2 25
2.34×
Q1 25
2.42×
Q4 24
2.38×
Q3 24
2.43×
Q2 24
2.63×
Q1 24
2.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
NREF
NREF
Operating Cash FlowLast quarter
$-22.1M
$-4.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
NREF
NREF
Q4 25
$-22.1M
$-4.5M
Q3 25
$-31.2M
$8.1M
Q2 25
$-12.1M
$3.3M
Q1 25
$-33.3M
$16.0M
Q4 24
$-17.9M
$4.4M
Q3 24
$-24.1M
$14.7M
Q2 24
$-5.0M
$-7.5M
Q1 24
$-18.1M
$17.7M
Free Cash Flow
CCCC
CCCC
NREF
NREF
Q4 25
Q3 25
$-31.6M
Q2 25
Q1 25
Q4 24
$-17.9M
Q3 24
$-24.1M
Q2 24
$-5.2M
Q1 24
FCF Margin
CCCC
CCCC
NREF
NREF
Q4 25
Q3 25
-281.5%
Q2 25
Q1 25
Q4 24
-346.5%
Q3 24
-157.2%
Q2 24
-43.1%
Q1 24
Capex Intensity
CCCC
CCCC
NREF
NREF
Q4 25
Q3 25
3.7%
Q2 25
Q1 25
Q4 24
0.1%
Q3 24
0.1%
Q2 24
1.6%
Q1 24
0.0%
Cash Conversion
CCCC
CCCC
NREF
NREF
Q4 25
-0.19×
Q3 25
0.16×
Q2 25
0.15×
Q1 25
0.62×
Q4 24
0.29×
Q3 24
0.63×
Q2 24
-0.62×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons